Jade Biosciences (JBIO) has an average rating of buy and mean price target of $38, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $18.59, Change: $-2.45, Percent Change: -11.64%
Revolution Medicines' (RVMD) full results from its RASolute-302 trial presented at a medical conference indicate that daraxonrasib is emerging as the "clear winner" for the second line treatment of pancreatic cancer, RBC Capital Markets said in a note Monday.The trial is an "inflection point" in second line pancreatic cancer treatment and for Revolution it "represents a large commercial opportunity," the note said.There is now a "clear near-term regulatory path" as well as optionality to bring the drug into other indications, for a potential opportunity of more than $10 billion, RBC said.The investment firm added that while the competitive landscape is intensifying, Revolution's new data sets a "high bar" and Revolution will likely stay the leader in the space.RBC has an outperform rating on Revolution and a $165 price target.Price: $159.93, Change: $+2.45, Percent Change: +1.56%
(Updates with statement from Dauch in the sixth paragraph).The United Auto Workers has called a strike at a Michigan factory owned by Dauch (DCH), a supplier of axles and driveline components for General Motors (GM) pickup trucks.The union said that about 1,000 unionized workers at the Michigan plant were set to walk off the job at midnight Sunday after contract talks failed to produce an agreement.The UAW said it is seeking higher wages as workers accepted significant pay cuts to help keep the plant operating during the 2008 financial crisis.According to the union, top wages at the facility currently reach $22 per hour after a five-year progression, compared with as much as $29 per hour in 2008.General Motors said in an emailed statement Monday that it is "closely monitoring" the labor dispute at Dauch's Three Rivers plant and assessing any potential impact on its operations.In a statement released on the London Stock Exchange, Dauch confirmed that it had not yet agreed on the terms of a new collective bargaining agreement with the union.Price: $81.92, Change: $-1.32, Percent Change: -1.59%
Church & Dwight (CHD) is well positioned to deliver growth despite a "difficult" macroeconomic environment, supported by its mix of value and premium brands, strong volume growth and disciplined acquisition strategy, RBC Capital Markets said in a June 1 report following meetings with the company's management team.Church & Dwight's portfolio is benefiting from consumer "trade-down" trends, particularly through brands such as Arm & Hammer in laundry and litter, making the company an outlier among consumer packaged goods peers, the report said.The firm highlighted multiple growth drivers, including distribution gains, international expansion, innovation and mergers and acquisitions. RBC also views Church & Dwight's recently announced $325 million acquisition of stain remover brand Miss Mouth's Messy Eater favorably, citing opportunities to expand the brand's retail presence.RBC also identified Therabreath and Hero as key "growth engines" and said the company remains prepared to capitalize on emerging trends, including artificial intelligence and evolving consumer behavior, according to the report.RBC has an outperform rating on Church & Dwight, with a price target of $114, adding that the company "remains one of our top ideas."Price: $95.73, Change: $+0.10, Percent Change: +0.10%